52 related articles for article (PubMed ID: 25143127)
1. Therapeutic effects of exon skipping and losartan on skeletal muscle of mdx mice.
Lee EJ; Kim AY; Lee EM; Lee MM; Min CW; Kang KK; Park JK; Hwang M; Kwon SH; Tremblay JP; Jeong KS
Pathol Int; 2014 Aug; 64(8):388-96. PubMed ID: 25143127
[TBL] [Abstract][Full Text] [Related]
2. Using a State-of-the-Art Toolbox to Evaluate Molecular and Functional Readouts of Antisense Oligonucleotide-Induced Exon Skipping in
Datson NA; Bijl S; Janson A; Testerink J; van den Eijnde R; Weij R; Puoliväli J; Lehtimäki K; Bragge T; Ahtoniemi T; van Deutekom JC
Nucleic Acid Ther; 2020 Feb; 30(1):50-65. PubMed ID: 31821107
[TBL] [Abstract][Full Text] [Related]
3. Targeted Antisense Oligonucleotide-Mediated Skipping of Murine
Trundle J; Lu-Nguyen N; Malerba A; Popplewell L
Int J Mol Sci; 2024 Jun; 25(11):. PubMed ID: 38892298
[TBL] [Abstract][Full Text] [Related]
4. Single nuclei transcriptomics of muscle reveals intra-muscular cell dynamics linked to dystrophin loss and rescue.
Scripture-Adams DD; Chesmore KN; Barthélémy F; Wang RT; Nieves-Rodriguez S; Wang DW; Mokhonova EI; Douine ED; Wan J; Little I; Rabichow LN; Nelson SF; Miceli MC
Commun Biol; 2022 Sep; 5(1):989. PubMed ID: 36123393
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study.
Voit T; Topaloglu H; Straub V; Muntoni F; Deconinck N; Campion G; De Kimpe SJ; Eagle M; Guglieri M; Hood S; Liefaard L; Lourbakos A; Morgan A; Nakielny J; Quarcoo N; Ricotti V; Rolfe K; Servais L; Wardell C; Wilson R; Wright P; Kraus JE
Lancet Neurol; 2014 Oct; 13(10):987-96. PubMed ID: 25209738
[TBL] [Abstract][Full Text] [Related]
6. Predictive markers of clinical outcome in the GRMD dog model of Duchenne muscular dystrophy.
Barthélémy I; Pinto-Mariz F; Yada E; Desquilbet L; Savino W; Silva-Barbosa SD; Faussat AM; Mouly V; Voit T; Blot S; Butler-Browne G
Dis Model Mech; 2014 Nov; 7(11):1253-61. PubMed ID: 25261568
[TBL] [Abstract][Full Text] [Related]
7. Ataluren: first global approval.
Ryan NJ
Drugs; 2014 Sep; 74(14):1709-14. PubMed ID: 25193627
[TBL] [Abstract][Full Text] [Related]
8. Novel and optimized strategies for inducing fibrosis in vivo: focus on Duchenne Muscular Dystrophy.
Pessina P; Cabrera D; Morales MG; Riquelme CA; Gutiérrez J; Serrano AL; Brandan E; Muñoz-Cánoves P
Skelet Muscle; 2014; 4():7. PubMed ID: 25157321
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of muscle fibrosis results in increases in both utrophin levels and the number of revertant myofibers in Duchenne muscular dystrophy.
Levi O; Genin O; Angelini C; Halevy O; Pines M
Oncotarget; 2015 Sep; 6(27):23249-60. PubMed ID: 26015394
[TBL] [Abstract][Full Text] [Related]
10. Forelimb treatment in a large cohort of dystrophic dogs supports delivery of a recombinant AAV for exon skipping in Duchenne patients.
Le Guiner C; Montus M; Servais L; Cherel Y; Francois V; Thibaud JL; Wary C; Matot B; Larcher T; Guigand L; Dutilleul M; Domenger C; Allais M; Beuvin M; Moraux A; Le Duff J; Devaux M; Jaulin N; Guilbaud M; Latournerie V; Veron P; Boutin S; Leborgne C; Desgue D; Deschamps JY; Moullec S; Fromes Y; Vulin A; Smith RH; Laroudie N; Barnay-Toutain F; Rivière C; Bucher S; Le TH; Delaunay N; Gasmi M; Kotin RM; Bonne G; Adjali O; Masurier C; Hogrel JY; Carlier P; Moullier P; Voit T
Mol Ther; 2014 Nov; 22(11):1923-35. PubMed ID: 25200009
[TBL] [Abstract][Full Text] [Related]
11. A sensitive, reproducible and objective immunofluorescence analysis method of dystrophin in individual fibers in samples from patients with duchenne muscular dystrophy.
Beekman C; Sipkens JA; Testerink J; Giannakopoulos S; Kreuger D; van Deutekom JC; Campion GV; de Kimpe SJ; Lourbakos A
PLoS One; 2014; 9(9):e107494. PubMed ID: 25244123
[TBL] [Abstract][Full Text] [Related]
12. Whole body periodic acceleration is an effective therapy to ameliorate muscular dystrophy in mdx mice.
Altamirano F; Perez CF; Liu M; Widrick J; Barton ER; Allen PD; Adams JA; Lopez JR
PLoS One; 2014; 9(9):e106590. PubMed ID: 25181488
[TBL] [Abstract][Full Text] [Related]
13. Loss of nNOS inhibits compensatory muscle hypertrophy and exacerbates inflammation and eccentric contraction-induced damage in mdx mice.
Froehner SC; Reed SM; Anderson KN; Huang PL; Percival JM
Hum Mol Genet; 2015 Jan; 24(2):492-505. PubMed ID: 25214536
[TBL] [Abstract][Full Text] [Related]
14. A rebirth for drisapersen in Duchenne muscular dystrophy?
Hoffman E
Lancet Neurol; 2014 Oct; 13(10):963-5. PubMed ID: 25209737
[No Abstract] [Full Text] [Related]
15. Magnetic resonance imaging and spectroscopy assessment of lower extremity skeletal muscles in boys with Duchenne muscular dystrophy: a multicenter cross sectional study.
Forbes SC; Willcocks RJ; Triplett WT; Rooney WD; Lott DJ; Wang DJ; Pollaro J; Senesac CR; Daniels MJ; Finkel RS; Russman BS; Byrne BJ; Finanger EL; Tennekoon GI; Walter GA; Sweeney HL; Vandenborne K
PLoS One; 2014; 9(9):e106435. PubMed ID: 25203313
[TBL] [Abstract][Full Text] [Related]
16. Biodistribution studies of polymeric nanoparticles for drug delivery in mice.
Falzarano MS; Bassi E; Passarelli C; Braghetta P; Ferlini A
Hum Gene Ther; 2014 Nov; 25(11):927-8. PubMed ID: 25244215
[TBL] [Abstract][Full Text] [Related]
17. Analyses of the presence of mutations in Dystrophin protein to predict their relative influences in the onset of Duchenne Muscular Dystrophy.
Bhattacharya S; Das A; Dasgupta R; Bagchi A
Cell Signal; 2014 Dec; 26(12):2857-64. PubMed ID: 25220406
[TBL] [Abstract][Full Text] [Related]
18. Beta-blockers in Children with Duchenne Cardiomyopathy.
Matsumura T
Rev Recent Clin Trials; 2014; 9(2):76-81. PubMed ID: 25198739
[TBL] [Abstract][Full Text] [Related]
19. When a mid-intronic variation of DMD gene creates an ESE site.
Trabelsi M; Beugnet C; Deburgrave N; Commere V; Orhant L; Leturcq F; Chelly J
Neuromuscul Disord; 2014 Dec; 24(12):1111-7. PubMed ID: 25193336
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
